Showing 13 posts of 13 posts found.


Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data

September 17, 2020
Research and Development Novartis, Tafinlar, mekinist, melanoma

Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …

NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma

September 17, 2018
Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma

NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …


FDA approves Novartis combo in rare thyroid cancer subtype

May 8, 2018
Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer

The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …


Novartis combo expands into lung cancer with EU approval

April 4, 2017
Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist

Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …


Novartis says Phase II data for rare lung cancer showed overall response rate of 63%

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist

Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …

Astrazeneca image

AstraZeneca bags another FDA orphan status in cancer

April 17, 2015
Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib

The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …

Roche wins drug discovery award for Gazyvaro

December 18, 2014
Sales and Marketing BPS, British Pharmacological Society, GSK, Gazyvaro, Roche, mekinist

Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society …

Zelboraf image

Roche submits melanoma drug to FDA

December 15, 2014
Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib

Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …

GSK melanoma drugs beat rival in new study

July 18, 2014
Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma

GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …

gsk image

Mekinist shown EU green light

July 7, 2014
Sales and Marketing CHMP, Cancer, GSK, Tafinlar, braf, mekinist, melanoma

The European Commission has given GlaxoSmithKline’s melanoma drug Mekinist the thumbs-up following a positive opinion in April from the European …

gsk image

Mekinist shown green light by CHMP

April 28, 2014
Sales and Marketing CHMP, Cancer, GSK, mekinist, oncology, trametinib

GlaxoSmithKline’s melanoma drug Mekinist is virtually nailed on to be given approval in the European Union following a positive opinion …

gsk image

FDA approves GSK cancer combo

January 14, 2014
Research and Development, Sales and Marketing FDA, GSK, Tafinlar, mekinist

US regulators have shown the green light to a combination of two GlaxoSmithKline skin cancer drugs, Mekinist and Tafinlar, to …

GSK image

GSK files cancer combination

July 10, 2013
Sales and Marketing FDA, GSK, Tafinlar, mekinist

GlaxoSmithKline has put in supplemental applications for its Tafinlar/Mekinist combination – a pair of drugs which analysts predict may have …

Latest content